PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R.
Janku F, et al. Among authors: luthra r.
J Clin Oncol. 2012 Mar 10;30(8):777-82. doi: 10.1200/JCO.2011.36.1196. Epub 2012 Jan 23.
J Clin Oncol. 2012.
PMID: 22271473
Free PMC article.